Equine Genetics Market Size, Share and Growth Outlook, 2026

Equine Genetics Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Equine Genetics Market size is forecast to increase from $532.24 Million in 2026 to $999.83 Million in 2034 at a CAGR of 8.2% between 2026 and 2034.

The Equine Genetics market report provides detailed analysis and outlook of Equine Genetics segments including By Test (Parentage & Lineage Verification Testing, Hereditary & Genetic Disease Testing, Performance & Athletic Trait Profiling, Coat Color & Phenotypic Marker Testing), By Biological Sample Type (Hair Root Samples, Whole Blood Samples, Tissue Samples & Biopsies, Buccal ), By Equine Application Class (Professional Racing & Syndicates, Performance Sports, Recreational & Leisure Companion Horses), By End-User (Professional Horse Breeders & Stud Operations, Veterinary Clinics & Diagnostics Practitioners, Equine Insurance Providers & Racing Authorities, Academic, Ocular, & Genomic Research Institutions) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Equine Genetics Industry Overview

Advanced Genomic Testing Expanding Equine Genetic Verification

The equine genetics industry is experiencing significant advancement through the growing adoption of genomic testing technologies for parentage verification, ancestry tracing, and breed authentication. The Veterinary Genetics Laboratory (VGL) at the University of California, Davis has expanded educational and clinical initiatives focused on advanced animal genomics, strengthening the deployment of sophisticated genetic testing pipelines across the equine sector. These programs support parentage testing, genetic coat color inheritance analysis, and forensic DNA applications that help registry organizations verify purebred bloodlines and detect ancestry fraud. Genetic mapping technologies are also increasingly utilized in equine law enforcement investigations involving theft, ownership disputes, and animal welfare cases. As breeders and breed associations prioritize pedigree accuracy and genetic transparency, demand for comprehensive equine DNA testing services continues to increase globally.

Genomic Research Supporting Performance and Disease Management

Ongoing molecular and genomic research is transforming the understanding of equine performance traits and hereditary disease susceptibility. The research initiative titled Exploring Equine Genetics: Quantitative, Molecular, and Genomic Insights has been established to conduct comprehensive multi-breed genomic studies across horses and donkeys. The program focuses on identifying genetic markers associated with athletic performance, musculoskeletal characteristics, metabolic efficiency, and inherited disorders. These investigations are helping breeders make more informed selection decisions while promoting sustainable breeding practices. In addition, the initiative addresses concerns regarding declining genetic diversity within elite racing and sport horse populations caused by intensive line-breeding. Growing investments in equine genomics are strengthening precision breeding strategies and supporting long-term herd health management throughout the industry.

Genetic Screening Programs Driving Preventive Breeding Strategies

The implementation of advanced genetic screening panels is becoming a critical component of equine breeding programs. Following extensive multi-center gene-mapping studies, equine geneticists have standardized testing protocols for inherited neuromuscular and metabolic disorders, including Polysaccharide Storage Myopathy (PSSM) and Glycogen Branching Enzyme Deficiency (GBED). Commercial genetics laboratories have incorporated these discoveries into expanded screening services, allowing breeders to identify carriers of harmful recessive mutations before breeding decisions are made. Breed registries, particularly within draft horse and Quarter Horse populations, are increasingly adopting mandatory pre-breeding stallion testing requirements to reduce the prevalence of hereditary diseases. These preventive genetic management practices are improving population health, enhancing breeding efficiency, and supporting responsible equine genetic stewardship.

Equine Genetics Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Equine Genetics market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Neogen Corporation, Zoetis Inc., Animal Genetics, Inc., Genus plc, Weatherbys Scientific, Etalon Diagnostics (Etalon DX), Practical Genetics LLC, CAG GmbH (Center for Animal Genetics), UC Davis Veterinary Genetics Laboratory, Basepaws, Inc. (Zoetis). The Equine Genetics market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Equine Genetics industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Equine Genetics Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Equine Genetics companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Equine Genetics markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Equine Genetics Market Competitive Benchmarking and Company Analysis

Leading companies in Equine Genetics industry include- Neogen Corporation, Zoetis Inc., Animal Genetics, Inc., Genus plc, Weatherbys Scientific, Etalon Diagnostics (Etalon DX), Practical Genetics LLC, CAG GmbH (Center for Animal Genetics), UC Davis Veterinary Genetics Laboratory, Basepaws, Inc. (Zoetis). The Equine Genetics market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Equine Genetics Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Equine Genetics market remains one of the strongest-performing segments in the country.
The US Equine Genetics Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Equine Genetics market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Equine Genetics industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Equine Genetics markets

Canada's strong Equine Genetics sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Equine Genetics market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Equine Genetics Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Equine Genetics market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Equine Genetics population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Equine Genetics industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Equine Genetics market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Equine Genetics sales through 2034

France Equine Genetics companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Equine Genetics Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Equine Genetics distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Equine Genetics Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Equine Genetics market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Equine Genetics industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Equine Genetics industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Equine Genetics Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Equine Genetics market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Equine Genetics market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Equine Genetics Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Equine Genetics Market Segmentation

By Test
Parentage & Lineage Verification Testing
Hereditary & Genetic Disease Testing
Performance & Athletic Trait Profiling
Coat Color & Phenotypic Marker Testing
By Biological Sample Type
Hair Root Samples
Whole Blood Samples
Tissue Samples & Biopsies
Buccal
By Equine Application Class
Professional Racing & Syndicates
Performance Sports
Recreational & Leisure Companion Horses
By End-User
Professional Horse Breeders & Stud Operations
Veterinary Clinics & Diagnostics Practitioners
Equine Insurance Providers & Racing Authorities
Academic, Ocular, & Genomic Research Institutions

Top Companies in Equine Genetics Industry

Neogen Corporation
Zoetis Inc.
Animal Genetics, Inc.
Genus plc
Weatherbys Scientific
Etalon Diagnostics (Etalon DX)
Practical Genetics LLC
CAG GmbH (Center for Animal Genetics)
UC Davis Veterinary Genetics Laboratory
Basepaws, Inc. (Zoetis)

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025